These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3073044)

  • 1. Bactericidal effect of ceftriaxone versus imipenem plus cilastatin in bronchial secretion.
    Fraschini F; Scaglione F; Cogo R; Casali W; Falchi M; Gattei G
    Chemotherapy; 1988; 34 Suppl 1():3-15. PubMed ID: 3073044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
    Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
    Stiefel U; Pultz NJ; Donskey CJ
    Antimicrob Agents Chemother; 2007 Jan; 51(1):372-5. PubMed ID: 17043115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of amikacin and imipenem alone and in combination against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Máthé A; Szabó D; Anderlik P; Rozgonyi F; Nagy K
    Diagn Microbiol Infect Dis; 2007 May; 58(1):105-10. PubMed ID: 17300908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)].
    Goto H; Takeda H; Kawai S; Watanabe T; Okazaki M; Shimada K; Nakano K; Yokouchi H; Ikemoto H; Mori T; Igari J; Oguri T; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Kudo K; Kobayashi N; Tanaka T; Sumitomo M; Matsushima T; Oka M; Niki Y; Suga M; Tosaka M; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Nasu M; Hiramatsu K; Oikawa S
    Jpn J Antibiot; 2006 Oct; 59(5):323-54. PubMed ID: 17180803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
    Pillay T; Pillay DG; Adhikari M; Sturm AW
    Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.
    Shaaban MI; Shaker MA; Mady FM
    J Nanobiotechnology; 2017 Apr; 15(1):29. PubMed ID: 28399890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
    Daimon Y
    Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of quantitative bacteriological examination of sputum in the evaluation of the effectiveness of chemotherapy of bacterial respiratory tract infections. II. Clinical studies].
    Nikodemowicz E; Owsiński J; Przybyłkiewicz Z; Kasprowicz A; Maternowska W; Kamińska M; Walaszek K; Prus F
    Pneumonol Pol; 1980 Aug; 48(8):545-22. PubMed ID: 6968434
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia].
    Toyonaga Y; Kanemura H; Kitano M; Mitsui Y; Ishihara T; Hoshiai M; Ohno R
    Jpn J Antibiot; 1999 Apr; 52(4):322-32. PubMed ID: 10396689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections.
    Hirata-Dulas CA; Stein DJ; Guay DR; Gruninger RP; Peterson PK
    J Am Geriatr Soc; 1991 Oct; 39(10):979-85. PubMed ID: 1918785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of quantitative bacteriological examination of sputum in the evaluation of the effectiveness of chemotherapy of bacterial respiratory tract infections. I. Bacteriological studies].
    Przybyłkiewicz Z; Nikodemowicz E; Kasprowicz A; Owsiński J
    Pneumonol Pol; 1980 Aug; 48(8):535-43. PubMed ID: 6775309
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antimicrobial activities of ceftriaxone against fresh, clinically isolated strains].
    Suzuki Y; Koguchi M; Tanaka S; Fukayama S; Ishihara R; Deguchi K; Oda S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1996 Jan; 49(1):83-94. PubMed ID: 8851307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative evaluation of the in vitro and in vivo antibacterial activity of ceftriaxone and piperacillin: determination of the inhibitory quotient in bronchial secretions].
    Fraschini F; Scaglione F; Ripamonti L; Cogo R; Casali W
    Recenti Prog Med; 1988 May; 79(5):224-9. PubMed ID: 3051198
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain.
    Isla A; Trocóniz IF; Canut A; Labora A; Martín-Herrero JE; Pedraz JL; Gascón AR
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):167-73. PubMed ID: 21334779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses.
    Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R
    J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.